← 返回

育龄期女性一生累积生殖激素暴露与 TIL(肿瘤浸润淋巴细胞)、CD4+和 CD8+T 细胞之间的关联

英文原题:Association between cumulative lifetime exposure to reproductive hormones and tumor-infiltrating lymphocytes, CD4 +, and CD8 + T cells among women with breast cancer.

查看英文原题

Association between cumulative lifetime exposure to reproductive hormones and tumor-infiltrating lymphocytes, CD4 +, and CD8 + T cells among women with breast cancer.

PubMed 2026/07/10(内容时间) Cancer Immunol Immunother Q1 · IF 5.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

终生内源性激素暴露与总体较低的 CD8+ T 细胞密度相关,探索性发现在 HR+/HER2-肿瘤女性中 TIL 水平较低。终生外源性激素暴露与较低的全因死亡风险相关,且可能因 TIL 水平而异。

研究思路结论见上方概要

生殖激素可能影响对肿瘤的免疫反应。TIL(肿瘤浸润淋巴细胞)(TILs)、CD4+和CD8+T细胞密度是免疫活性和乳腺癌预后的标志物。我们研究了乳腺癌女性患者一生中生殖激素暴露、肿瘤免疫浸润与生存之间的关联。

研究纳入女性健康圈研究和女性健康圈随访研究中的浸润性乳腺癌病例。终生内源性激素暴露(LHEendo)定义为生育年数加妊娠持续时间减去母乳喂养持续时间;终生外源性激素暴露(LHEexo)定义为口服避孕药和激素替代疗法使用的累计持续时间之和。TILs按0至100%间质面积的有序百分比值评分;CD4+/CD8+T细胞密度通过免疫组织化学定量。TILs采用有序logistic回归建模,CD4+/CD8+T细胞密度在密度值为阳性的参与者中采用gamma广义线性模型建模,协变量通过有向无环图选择。总生存期采用Cox比例风险模型评估,乳腺癌特异性生存期采用Fine-Gray竞争风险模型评估。

在1195名具有有效TILs测量的女性中,分别有553名和610名拥有CD4+和CD8+T细胞密度数据。在所有肿瘤分子亚型中,LHEendo每增加1年,与CD8+T细胞密度下降2.85%相关(95% CI -5.14%, -0.61%)。在激素受体(HR)+/HER2-肿瘤女性中,LHEendo与处于较高TIL水平的几率降低相关(OR = 0.977, 95% CI 0.957, 0.997),尽管按分子亚型的交互作用无统计学显著性。LHEexo与全因死亡风险降低相关(HR = 0.979, 95% CI 0.960, 0.998)。按TIL分层的分析提示,这种关联在TILs 50%的女性中可能更为明显(HR = 0.90, 95% CI = 0.82, 0.99; P-interaction = 0.10)。

展开英文摘要原文

Reproductive hormones may influence immune responses to tumors. Tumor-infiltrating lymphocytes (TILs), CD4 +, and CD8 + T cell densities are markers of immune activity and breast cancer prognosis. We examined associations between lifetime reproductive hormone exposure, tumor immune infiltration, and survival among women with breast cancer.

The study included invasive breast cancer cases in the Women's Circle of Health Study and the Women's Circle of Health Follow-up Study. Lifetime endogenous hormone exposure (LHEendo) was defined as reproductive years plus pregnancy duration minus breastfeeding duration; lifetime exogenous hormone exposure (LHEexo) was defined as the combined cumulative duration of oral contraceptive and hormone replacement therapy use. TILs were scored as ordered percentage values from 0 to 100% stromal area; CD4 + /CD8 + T cell densities were quantified by immunohistochemistry. TILs were modeled using ordinal logistic regression, and CD4 + /CD8 + T cell densities were modeled using gamma generalized linear models among participants with positive density values, with covariates selected by directed acyclic graphs. Overall survival was assessed using Cox proportional hazards models, and breast cancer-specific survival was assessed using Fine-Gray competing-risk models.

Among 1195 women with valid TILs measurements, 553 and 610 had CD4 + and CD8 + T cell density data, respectively. Across all tumor molecular subtypes, a 1-year increment of LHEendo was associated with a 2.85% decrease in CD8 + T cell density (95% CI - 5.14%, - 0.61%). LHEendo was associated with lower odds of being in a higher TIL level among women with hormone receptor (HR) + /HER2- tumors (OR = 0.977, 95% CI 0.957, 0.997), although the interaction by molecular subtype was not statistically significant. LHEexo was associated with lower risk of all-cause mortality (HR = 0.979, 95% CI 0.960, 0.998). TIL-stratified analyses suggested that this association may be more apparent among women with TILs 50% (HR = 0.90, 95% CI = 0.82, 0.99; P-interaction = 0.10).

Lifetime endogenous hormone exposure was associated with lower CD8 + T cell density overall, with exploratory findings of lower TIL levels among women with HR + /HER2- tumors. Lifetime exogenous hormone exposure was associated with a lower risk of all-cause mortality, with possible variation by TIL levels.

论文信息

作者
Zhang Y、Akasheh RT、Omilian AR、Qin B、Zeinomar N、Yao S、Hong CC、Bandera EV
第一作者单位
Division of Cancer Prevention and Control, Department of Internal Medicine, The Ohio State University, 3650 Olentangy River Rd., Columbus, OH, 43214, USA.United States
通讯作者单位
Division of Cancer Prevention and Control, Department of Internal Medicine, The Ohio State University, 3650 Olentangy River Rd., Columbus, OH, 43214, USA. ting-yuan.cheng@osumc.edu.United States
期刊
Cancer immunology, immunotherapy : CII2026 Jul 10
原文标识
PubMed 42429947 · DOI 10.1007/s00262-026-04471-3